Seek Returns

ASND vs. PCVX: Ascendis Pharma vs. Vaxcyte Stock Comparison

How do Ascendis Pharma (ASND) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Ascendis Pharma (ASND) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
Profile ItemASNDPCVX
NameAscendis Pharma A/SVaxcyte Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization16.90 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 28, 2015June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ASND
PCVX
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Ascendis Pharma (ASND) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Ascendis Pharma (ASND) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Total Return (1Y)29.46%59.00%
Total Return (3Y, Annualized)40.62%11.29%
Total Return (5Y, Annualized)10.03%21.60%

Risk Profile

Drawdown History

ASND
PCVX
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Ascendis Pharma (ASND) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Volatility (1Y, Annualized)38.62%56.01%
Beta (5Y)0.381.26
Max Drawdown (5Y)-55.93%-76.22%
Avg. Volume (3M)698.39K2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ASND and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Sharpe Ratio (1Y)0.650.98
Sortino Ratio (1Y)0.991.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

118.78%

ASND
118.78%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

70.85%

ASND
70.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Ascendis Pharma (ASND) at 64.98% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

64.98%

Max
83.12%
ASND
64.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
ROE (TTM)118.78%-42.68%
ROA (TTM)9.58%-24.98%
Net Margin (TTM)70.85%0.00%
Operating Margin (TTM)64.98%0.00%
Gross Margin (TTM)91.30%0.00%

Growth

Revenue Growth

Only one side can be read here: Ascendis Pharma (ASND) reports revenue growth of 98.03%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Ascendis Pharma (ASND) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Revenue Growth (YoY)98.03%--
Revenue Growth (3Y CAGR)141.43%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Ascendis Pharma (ASND) at 2.99 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max
25.13
Q3
12.13
Median
5.52
ASND
2.99
Q1
2.47
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Ascendis Pharma (ASND) at 0.31 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
ASND
0.31
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Current Ratio (MRQ)2.994.56
Debt / Equity (MRQ)0.310.09
Net Debt / EBITDA-1.37--

Dividends

Dividend Yield (TTM)

Neither Ascendis Pharma (ASND) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Ascendis Pharma (ASND) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.68

Max
85.34
Q3
43.46
Median
26.69
ASND
19.68
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Ascendis Pharma (ASND), whose P/S ratio of 16.14 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.14

Max
58.18
Q3
25.77
ASND
16.14
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.45

Max
13.53
ASND
10.45
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Ascendis Pharma (ASND) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Ascendis Pharma (ASND) and Vaxcyte (PCVX)
MetricASNDPCVX
P/E Ratio (TTM)19.68--
P/S Ratio (TTM)16.14--
P/B Ratio (MRQ)10.453.83
Free Cash Flow Yield (TTM)0.08%-5.24%